Vinayak Nagaraja1, Guy D Eslick1. 1. The Whiteley-Martin Research Centre, Discipline of Surgery, The Sydney Medical School Nepean, Penrith, NSW 2751, Australia.
Abstract
BACKGROUND: Since the advent and the success of adjuvant medical therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the form of trastuzumab there has been increasing interest in the development of similar therapies in other solid organ malignancies including gastric cancer and oesophageal cancer. Over the years, multiple observational studies have been inconsistent. Several meta-analyses have been published looking at the association between HER2 and gastric cancer and oesophageal cancer. This review aims to summarize the meta-analytic evidence for the association between HER2 in gastric and oesophageal cancer. METHODS: A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane Library, Google Scholar, Science Direct, and Web of Science. RESULTS: Of the articles selected, only nine studies met full criteria. Six of them reviewed the role of HER2 in gastric cancer and the remaining three reviewed its role in oesophageal cancer. CONCLUSIONS: The current evidence regarding the role of HER2 is unclear. However, it clearly plays a key role in the pathogenesis of gastric and oesophageal carcinomas. Targeted therapy towards this subgroup (despite variable frequency and association with survival) would offer a mortality benefit and improve survival.
BACKGROUND: Since the advent and the success of adjuvant medical therapy for humanepidermal growth factor receptor 2 (HER2)-positive breast cancer in the form of trastuzumab there has been increasing interest in the development of similar therapies in other solid organ malignancies including gastric cancer and oesophageal cancer. Over the years, multiple observational studies have been inconsistent. Several meta-analyses have been published looking at the association between HER2 and gastric cancer and oesophageal cancer. This review aims to summarize the meta-analytic evidence for the association between HER2 in gastric and oesophageal cancer. METHODS: A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane Library, Google Scholar, Science Direct, and Web of Science. RESULTS: Of the articles selected, only nine studies met full criteria. Six of them reviewed the role of HER2 in gastric cancer and the remaining three reviewed its role in oesophageal cancer. CONCLUSIONS: The current evidence regarding the role of HER2 is unclear. However, it clearly plays a key role in the pathogenesis of gastric and oesophageal carcinomas. Targeted therapy towards this subgroup (despite variable frequency and association with survival) would offer a mortality benefit and improve survival.
Entities:
Keywords:
Human epidermal growth factor receptor 2 (HER2); esophageal cancer; gastric cancer
Authors: Klaus Aumayr; Afschin Soleiman; Klaus Sahora; Martin Schindl; Gregor Werba; Sebastian F Schoppmann; Peter Birner Journal: Appl Immunohistochem Mol Morphol Date: 2014
Authors: Frédérique Penault-Llorca; Michael Bilous; Mitch Dowsett; Wedad Hanna; Robert Yoshiyuki Osamura; Josef Rüschoff; Marc van de Vijver Journal: Am J Clin Pathol Date: 2009-10 Impact factor: 2.493
Authors: Roberto de Moraes Cordts Filho; Paulo Kassab; Laura Carolina Lopez Claro; Mabel Tatty de Medeiros Fracassi; Patrícia Colombo-Souza; Daniel Kenji Fukuhara; Fábio Rodrigues Thuler; Wilson Rodrigues de Freitas Junior; Elias Jirjoss Ilias; Carlos Alberto Malheiros Journal: ScientificWorldJournal Date: 2016-12-25
Authors: Ferdinando Maria Milazzo; Anna Maria Anastasi; Caterina Chiapparino; Antonio Rosi; Barbara Leoni; Loredana Vesci; Fiorella Petronzelli; Rita De Santis Journal: Oncotarget Date: 2017-04-04
Authors: Joe Abdo; Carrie A Bertellotti; David L Cornell; Devendra K Agrawal; Sumeet K Mittal Journal: Front Oncol Date: 2017-07-18 Impact factor: 6.244